Efficacy and safety of 3 doses of S 38093 (2, 5 and 20 mg/day) versus placebo in patients with mild to moderate Alzheimer's disease. A 24- week international, multi-centre, randomised, double-blind, placebo-controlled phase IIb study followed by a 24-week extension period

Trial Profile

Efficacy and safety of 3 doses of S 38093 (2, 5 and 20 mg/day) versus placebo in patients with mild to moderate Alzheimer's disease. A 24- week international, multi-centre, randomised, double-blind, placebo-controlled phase IIb study followed by a 24-week extension period

Completed
Phase of Trial: Phase II

Latest Information Update: 19 Aug 2014

At a glance

  • Drugs S 38093 (Primary)
  • Indications Alzheimer's disease
  • Focus Pharmacogenomic; Registrational; Therapeutic Use
  • Sponsors Servier
  • Most Recent Events

    • 05 Nov 2013 Status changed from recruiting to completed as reported by ISRCTN: Current Controlled Trials record.
    • 01 Aug 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top